PPARs and their role in cancer
Journal Title: OncoReview - Year 2011, Vol 1, Issue 4
Abstract
Peroxisome proliferator activated receptors are members of a very common group of steroid nuclear receptors. The aim of the study was to present actual knowledge regarding the role of PPAR in cancerogenesis. Three types of PPAR are identified: PPARα, PPARβ/δ and PPARγ. They all belong to the superfamily of nuclear receptors and are similar to vitamine D receptor, thyroid hormone receptor and retinoid receptor. In physiological conditions PPAR participates in adipocyte differentiation, lipid storage, regulation of inflamatory reaction as well as in glucose metabolism. Since 1990s the role of PPAR in cancerogenesis has been emphasised. PPARα plays a significant role in cancerogenesis of hepatocellular cancer. Activation of PPARβ/δ is crucial in developing the colorectal cancer in patients with familial adenomatous polyposis. The role of PPARγ in cancerogenesis is more complex. PPARγ can inhibit proliferation of cancer cells and they have some antiangiogenic and proapoptic activity in tumor. So far the clinical use of PPAR ligands as anticancer agents is limited to phase I and II clinical trials, available results of which are unclear.
Authors and Affiliations
Łukasz Głogowski, Anna Żmuda-Siedlarczyk, Andrzej Witkoś, Zofia Rusinowska, Teresa Kokot, Małgorzata Muc-Wierzgoń, Ewa Nowakowska-Zajdel
Perikardiocenteza i aspekty terapii doosierdziowej u chorych onkologicznych - opis przypadku
Przebieg procesu nowotworowego z towarzyszącym wysiękiem płynu do worka osierdziowego ma zmienną dynamikę, a obraz kliniczny i nasilenie objawów związane są bezpośrednio ze stopniem zaburzeń hemodynamicznych i szybkością...
Tyrosine kinase inhibitors in hematologic malignancy: should we be concerned?
Rola eksemestanu w leczeniu raka piersi
Leczenie hormonalne jest jedną z podstawowych opcji terapeutycznych w leczeniu raka piersi, zarówno miejscowo zaawansowanego, jak i przerzutowego. Standardem od wielu lat pozostaje tamoksyfen, jednak wyniki nowych badań...
Quality of life in oncology and quality of life in course of molecularly targeted therapy in patients diagnosed with metastatic renal-cell carcinoma
Introduction of molecularly targeted agents into clinical practice has led to marked progress in pharmacotherapy of advanced renal cell carcinoma. There have been six drugs of the therapeutic class registered to date. Fu...
Therapeutic rehabilitation of cancer patients. Why and what for?
Types of oncological rehabilitation and its objectives are described. It includes information on many manifestations of oncological diseases that an internist has to deal with, which are conditioned not only by the oncol...